Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Weesziekten en weesgeneesmiddelen • Weesziekte of zeldzame ziekte: Prevalentie < 1/2000 Bv: mucoviscidose 1/5000, hemofilie 1/10.000 Maar: ziekte van Crohn 6/2000, ijzerstapelingsziekte (hemochromatose) 1/200 • Weesgeneesmiddel: een geneesmiddel dat enkel (vooral?) dient om een weesziekte te behandelen Orphan drug regulation • United States: Orphan Drug Act (1983) • Europe (2000) Incentives I. Market exclusivity for a period of 10 years protects against a ‘similar’ drug being authorized in the EU for the same therapeutic indication II. Protocol and scientific assistance wrt clinical and non-clinical aspects of drug development III. Access to the centralized registration procedure IV. Access to EU-funded research V. Incentives undertaken on a national level + Fee reductions such as full or partial EMA fee waivers Criteria for orphan designation (Art. 3) A medicinal product intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition 1° that affects not more that 5 in 10 000 people in the Community (prevalence criterion) OR 2° that without incentives it would be unlikely to generate sufficient return the justify the investment (return on investment criterion) There is no satisfactory method of diagnosis, prevention or treatment of the condition. AND OR If such a method does exist, that the medicinal product will be of significant benefit to those affected. Current status • Orphan designations (Westermark, 2011) Current status • Market authorizations 60 authorized orphan drugs (October 2011) (KCE, 2010)